Fluidigm

BioMark Announces Update from Ongoing Clinical Trial Using Its Lung Cancer Liquid Biopsy Test as It Prepares for Commercial Launch

Retrieved on: 
Wednesday, January 11, 2023
HCL, Climate change, Ageing, Hospital, BUX, OTC Markets Group, Cancer, Delhi Pharmaceutical Science and Research University, Hospices Civils de Lyon, Lung cancer, CSE, FSE, Certification, Smoking, LDT, Biomarker, Risk assessment, Genetics, CT, Partnership, History, ESMO, ISO, Fluidigm, Clinical trial, Glioblastoma, Research university, Institut Universitaire de France, Incidence, Medical imaging

As clinical trial success relies on effective patient recruitment, BioMark is delighted to announce today that enrollment for its pivotal lung cancer screening study exceeded 1000 participants in less than one year.

Key Points: 
  • As clinical trial success relies on effective patient recruitment, BioMark is delighted to announce today that enrollment for its pivotal lung cancer screening study exceeded 1000 participants in less than one year.
  • The Company also announces its first international patient recruited as part of a European prospective lung cancer screening trial in France known as the ILYAD study.
  • The Company intends to pursue clinical validation of the test as a laboratory developed test (LDT) in parallel with these ongoing studies.
  • The BioMark Lung Cancer Risk Assessment Test will be available through its Quebec-based accredited laboratory, BioMark Diagnostic Solutions Inc., within approximately 9 - 12 months based on the completion of the ISO 15-189 certification.

Single Cell Technology Competitive Landscape Report 2022: 38 Main Players Accounted for $860 Million in 2021

Retrieved on: 
Thursday, December 29, 2022
Spatial analysis, Genomics, History, SCT, BD, Cell biology, Libyan Post Telecommunications & Information Technology Company, Immortalised cell line, Fine chemical, Microscope, Fluidigm

DUBLIN, Dec. 29, 2022 /PRNewswire/ -- The "Comprehensive Single Cell Technology 2022" report has been added to ResearchAndMarkets.com's offering.

Key Points: 
  • DUBLIN, Dec. 29, 2022 /PRNewswire/ -- The "Comprehensive Single Cell Technology 2022" report has been added to ResearchAndMarkets.com's offering.
  • The market size is ~ $0.86 billion USD in 2021, at a CAGR of ~28% when calculated based on the main 38 companies only.
  • There are 58+ commercial SCT products from 52 companies and over 30 pre-commerce-stage startups to enter the market in the next few years.
  • Primarily, the SCT market is young and complex: over 75% of the products were launched within the last 7 years.

Velo3D to Transform its Production Operations With the Hiring of Brad Kreger as Executive Vice President of Operations

Retrieved on: 
Tuesday, December 13, 2022
Other Manufacturing, Technology, Public Relations, Investor Relations, Chemicals, Plastics, Communications, Manufacturing, Machine Tools, Metalworking & Metallurgy, Hardware, Consumer Electronics, Fluidigm, Bay, Honeywell, VELO, Flow, XC, Affymetrix, Lam Research, SpaceX, Thermo Fisher Scientific, Global Operations, Battlecross, Quality assurance, NYSE, San Francisco, AM, All rights reserved, VLD, Multimedia, Growth, Senior, Aviation, SAPPHIRE, Defence Intelligence Fusion Centre, Forecasting, FLOW, Management, 3D printing, Risk management, Sapphire, Operation

Kreger brings decades of experience overseeing and rapidly scaling operations in hardware production, including tenures at Thermo Fisher Scientific and its subsidiary Affymetrix, and Fluidigm Corporation.

Key Points: 
  • Kreger brings decades of experience overseeing and rapidly scaling operations in hardware production, including tenures at Thermo Fisher Scientific and its subsidiary Affymetrix, and Fluidigm Corporation.
  • View the full release here: https://www.businesswire.com/news/home/20221213005067/en/
    Brad Kreger, Executive Vice President of Operations at Velo3D (Graphic: Business Wire)
    Kregers career has centered around early-stage companies that are scaling the manufacturing of hardware while also making improvements in quality and cost.
  • I look forward to seeing Brad optimize our operations to accelerate the production our Sapphire and Sapphire XC printers, increase our manufacturing capabilities, and reach our production goals for 2023 and beyond.
  • In his new role overseeing production, Kreger will lead all operations activities at Velo3D, including global logistics, manufacturing, quality, and procurement.

Standard BioTools Authorizes up to $20 Million of Share Repurchases

Retrieved on: 
Monday, November 28, 2022
Regulation, SAN, Disclosure, Microfluidics, Hand, Biotechnology, Social media, Government, Standard, Annual report, Research, Disease, Health, Regulation Fair Disclosure, Immunotherapy, Risk management, Fluidigm

The repurchase program may be suspended or discontinued at any time at the Company's discretion.

Key Points: 
  • The repurchase program may be suspended or discontinued at any time at the Company's discretion.
  • Standard BioTools works with leading academic, government, pharmaceutical, biotechnology, plant and animal research, and clinical laboratories worldwide, focusing on the most pressing needs in translational and clinical research, including oncology, immunology, and immunotherapy.
  • Standard BioTools, the Standard BioTools logo, Fluidigm, the Fluidigm logo, and Unleashing tools to accelerate breakthroughs in human health are trademarks and/or registered trademarks ofStandard BioTools Inc.or its affiliates inthe United Statesand/or other countries.
  • Therefore, investors should monitor Standard BioTools website and its social media accounts in addition to following its press releases,SECfilings, public conference calls, and webcasts.

LevitasBio Strengthens its C-Suite

Retrieved on: 
Monday, November 28, 2022
Science, Other Science, Biotechnology, Research, Oncology, General Health, Health, Genetics, Science, History, Cell, Bias, Applied Biosystems, Long, Life Technologies, Singularis Holdings Limited (in liquidation) v Daiwa Capital Markets Europe Limited, GameChanger, Marketing, Fluidigm, Senior, Pacific Biosciences, Dominique, Thermo Fisher Scientific, Harvard Business School, Health, Percussion section, Acquisition, Management, Mobile phone, Fine chemical, Dionex

Dominique Remy-Renou, Senior Vice President of Global Commercial Operations, LevitasBio Europe BV

Key Points: 
  • Dominique Remy-Renou, Senior Vice President of Global Commercial Operations, LevitasBio Europe BV
    Ms. Remy-Renou has over 30 years experience leading, building, developing and managing global field operations in the life sciences tools industry.
  • I am thrilled to join the tremendous team at LevitasBio, said Dominique Remy-Renou, newly appointed Senior VP of Global Commercial Operations for LevitasBio Europe BV.
  • His ability to develop and implement growth strategies and his track record for driving commercial performance will bring welcome insights and strategic thinking to LevitasBio.
  • We couldnt be happier to welcome Dominique and Greg to the C-Suite and board of directors, respectively, stated Martin Pieprzyk, CEO of LevitasBio.

Standard BioTools Inc. Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

Retrieved on: 
Tuesday, November 22, 2022
SAN, National Stock Exchange of India, Microfluidics, Employment, Biotechnology, Government, Financial compensation, Standard, Research, Disease, Health, Immunotherapy, Plan, Fluidigm

The equity awards were approved in accordance with Nasdaq Listing Rule 5635(c)(4).

Key Points: 
  • The equity awards were approved in accordance with Nasdaq Listing Rule 5635(c)(4).
  • In connection with the individuals entering into employment with Standard BioTools as new employees, none of whom were previously employees or directors of Standard BioTools, the individuals received awards totaling an aggregate of 235,200 restricted stock units (RSU Awards).
  • Standard BioTools has an established portfolio of essential, standardized next-generation technologies that help biomedical researchers develop medicines faster and better.
  • Standard BioTools, the Standard BioTools logo, Fluidigm, the Fluidigm logo, and Unleashing tools to accelerate breakthroughs in human health are trademarks and/or registered trademarks of Standard BioTools Inc. or its affiliates in the United States and/or other countries.

Comprehensive Single Cell Technology 2022: 10x Genomics, Fluidigm, BD Biosciences, and Berkeley Light Lead the Way in Fast-Growing Sector - ResearchAndMarkets.com

Retrieved on: 
Tuesday, November 22, 2022
Health, Biotechnology, Libyan Post Telecommunications & Information Technology Company, Genomics, SCT, Cell biology, Immortalised cell line, History, Fine chemical, Microscope, Fluidigm

The "Comprehensive Single Cell Technology 2022" report has been added to ResearchAndMarkets.com's offering.

Key Points: 
  • The "Comprehensive Single Cell Technology 2022" report has been added to ResearchAndMarkets.com's offering.
  • There are +58 commercial SCT products from 52 companies and over 30 pre-commerce-stage startups to enter the market in the next few years.
  • Primarily, the SCT market is young and complex: over 75% of the products were launched within the last 7 years.
  • What are the important features in popular applications like cell line development, antibody discovery, and SC genomics?

Standard BioTools and Visiopharm Announce Partnership for the Development of Complete Image Analysis Solutions to be Packaged With Hyperion and Hyperion+ Imaging Systems

Retrieved on: 
Monday, November 7, 2022
Standard, Partnership, Research, Microfluidics, Solution, Industry, Forward-looking statement, Disclosure, Tumor microenvironment, Immunotherapy, Artificial intelligence, Hyperion, U.S. Securities and Exchange Commission, MCD, Government, Social media, Europa Imaging System, Data analysis, Private Securities Litigation Reform Act, Doctor of Philosophy, Regulation Fair Disclosure, Fluidigm, Biotechnology, Algorithm, Phenotype, SAN, GLOBE, Health, Annual report, Marie Cassidy, Drug development, Disease, Deep learning, Regulation, Television, Medical imaging, Medical device, IMC, Facebook

This close partnership offers one of the most effective solutions to date, in which Visiopharm software reads native MCD files, the output image file from Standard BioTools imaging systems, directly linking MCD Viewer to Phenoplex software.

Key Points: 
  • This close partnership offers one of the most effective solutions to date, in which Visiopharm software reads native MCD files, the output image file from Standard BioTools imaging systems, directly linking MCD Viewer to Phenoplex software.
  • We are delighted to embark on this partnership with Standard BioTools to bring our Phenoplex image analysis to Hyperion Imaging System users everywhere, said Louise Armstrong, PhD, Chief Commercial Officer at Visiopharm.
  • Its pioneering image analysis tools support thousands of scientists, pathologists, and image analysis experts in academic institutions, the biopharmaceutical industry, and diagnostic centers.
  • AI-based image analysis and tissue mining tools support research and drug development research worldwide, while CE-IVD APPs provide decision support.

Standard BioTools Announces Conference Call and Webcast of Third Quarter 2022 Financial Results

Retrieved on: 
Tuesday, October 25, 2022
SAN, LinkedIn, Disease, Government, Regulation Fair Disclosure, Standard, Biotechnology, Microfluidics, Research, Twitter, Solution, Industry, Health, Regulation, Immunotherapy, Social media, GLOBE, Disclosure, Medical device, Fluidigm, Facebook

ET, on November 8, 2022, to discuss third quarter 2022 financial results and operational progress.

Key Points: 
  • ET, on November 8, 2022, to discuss third quarter 2022 financial results and operational progress.
  • A press release outlining the financial results will be publicly distributed before the call.
  • Standard BioTools, the Standard BioTools logo, Fluidigm, the Fluidigm logo, and Unleashing tools to accelerate breakthroughs in human health are trademarks and/or registered trademarks ofStandard BioTools Inc.or its affiliates inthe United Statesand/or other countries.
  • Therefore, investors should monitor Standard BioTools website and its social media accounts in addition to following its press releases,SECfilings, public conference calls, and webcasts.

Resolve Biosciences Appoints Chief Commercial Officer to Drive Worldwide Adoption of Molecular Cartography™ Workflow

Retrieved on: 
Tuesday, October 25, 2022
Research, Genetics, Health Technology, Biotechnology, Other Health, Health, General Health, Science, Oncology, Adoption, Infection, Virtual reality, Agriculture, Science, Fluidigm, Workflow, Laboratory, Monheim am Rhein, NanoString Technologies, Neuroscience, Biology, List of life sciences, Developmental biology, Annual general meeting, Technology, University, United States Department of Agriculture South Building, Marketing, Cartography, Steinberg, Neurology, Commercial Operating System (COS), Convention center, CEO, Thermo Fisher Scientific, DNA, ASHG, COVID-19, View, Pharmaceutical industry, Microscope

Resolve Biosciences , the pioneer in Molecular Cartography technology, today announced the appointment of Paul Steinberg as Chief Commercial Officer.

Key Points: 
  • Resolve Biosciences , the pioneer in Molecular Cartography technology, today announced the appointment of Paul Steinberg as Chief Commercial Officer.
  • Most recently, he served as the Chief Commercial Officer at LevitasBio, a provider of innovative cellular processing and characterization technologies.
  • I am eager to join this talented team and to accelerate the process of delivering powerful Molecular Cartography results to labs around the world.
  • Resolve Biosciences, the Resolve Biosciences logo, and Molecular Cartography are trademarks of Resolve Biosciences.